LAG3 and cancer: Based on those findings, TIGIT monoclonal antibodies (such as tiragolumab, vibostolimab, ociperlimab) and multiple immune checkpoint blockade therapies (including PD-1/TIGIT, and PD-1/TIGIT/LAG-3), have all been developed for cancer treatment, and some are currently in ongoing clinical trials [56,57,99,100,101,102].